Cytomegalovirus in pediatric solid organ transplant recipients / Kevin J. Downes.

Format:

Video

Author/Creator:

Downes, Kevin J., author.

Language:

English

Subjects (All):

Transplantation of organs, tissues, etc.

Cytomegalovirus infections.

Physical Description:

1 online resource (1 streaming video file (38 min.))

Place of Publication:

London : Henry Stewart Talks, 2025.

System Details:

video file

Contents:

Introduction

Disclosures

Lecture outline

Cytomegalovirus (CMV)

Control of CMV

CMV: morbidity and mortality

Infection ≠ disease

CMV risk is determined by some factors

Preventing CMV infection post-transplant

CMW testing

Important caveats to viral load testing

When should CMV monitoring be performed?

CMV prevention & treatment

Effective strategies for CMV prevention

Pros and cons of CMV prevention strategies

CMV treatment

Approach to CMV management

Resistant and refractory CMV

Even with appropriate antiviral treatment, viral loads do not decline rapidly

Antiviral agents: prevent and treat CMV

Ganciclovir (GCV) & valganciclovir (VGCV): primary agents used in pSOT recipients

Bioavailability of GCV is poor, so VGCV is used most often for long-term CMV prevention

Optimal VGCV dosing in pSOT recipients is controversial

Foscarnet

Cidofovir

Letermovir (LET)

Letermovir vs. Valganciclovir

Letermovir in pSOT

Maribavir

Maribavir for refractory CMV infections (1)

Maribavir for refractory CMV infections (2)

Maribavir for refractory CMV infections (3)

Maribavir for refractory CMV infections (4)

Maribavir pros and cons

Adjunctive CMV treatments

Conclusions.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved August 19, 2025, from https://doi.org/10.69645/NHYJ1295.